NCT04706091View on ClinicalTrials.gov

Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 12, 2021

Primary Completion Date

October 20, 2023

Study Completion Date

October 20, 2023

Conditions
Restless Legs SyndromeInsomniaSleep Disorder
Interventions
DRUG

Suvorexant

10-mg or 20-mg suvorexant capsules

OTHER

Placebo

Matching placebo capsules

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT04706091 - Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia | Biotech Hunter | Biotech Hunter